Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.
Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, Oliva B, Moreno F, González-Suarez E, Vidal N, Andreu X, Seguí MA, Ballester R, Castella E, Sierra A. Martínez-Aranda A, et al. Among authors: andreu x. Oncotarget. 2015 Dec 29;6(42):44254-73. doi: 10.18632/oncotarget.5471. Oncotarget. 2015. PMID: 26497551 Free PMC article.
Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis.
Martínez-Aranda A, Hernández V, Moreno F, Baixeras N, Cuadras D, Urruticoechea A, Gil-Gil M, Vidal N, Andreu X, Seguí MA, Ballester R, Castella E, Sierra A. Martínez-Aranda A, et al. Among authors: andreu x. Front Oncol. 2017 Dec 1;7:283. doi: 10.3389/fonc.2017.00283. eCollection 2017. Front Oncol. 2017. PMID: 29250484 Free PMC article.
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Mateo F, et al. Among authors: andreu x. Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19. Oncogene. 2017. PMID: 27991928 Free PMC article.
Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status.
Fernández-Morales LA, Seguí MA, Andreu X, Dalmau E, Sáez A, Pericay C, Santos C, Montesinos J, Gallardo E, Arcusa A, Saigí E. Fernández-Morales LA, et al. Among authors: andreu x. Clin Breast Cancer. 2007 Apr;7(7):559-64. doi: 10.3816/CBC.2007.n.012. Clin Breast Cancer. 2007. PMID: 17509165 Clinical Trial.
Interval breast cancers in a community screening programme: frequency, radiological classification and prognostic factors.
Baré M, Sentís M, Galceran J, Ameijide A, Andreu X, Ganau S, Tortajada L, Planas J; Breast Cancer Screening Programme (BCSP) of Sabadell Cerdanyola Research Group on Interval Cancers. Baré M, et al. Among authors: andreu x. Eur J Cancer Prev. 2008 Oct;17(5):414-21. doi: 10.1097/CEJ.0b013e3282f75ef5. Eur J Cancer Prev. 2008. PMID: 18714182
Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
O'Loughlin M, Andreu X, Bianchi S, Chemielik E, Cordoba A, Cserni G, Figueiredo P, Floris G, Foschini MP, Heikkilä P, Kulka J, Liepniece-Karele I, Regitnig P, Reiner A, Ryska A, Sapino A, Shalaby A, Stovgaard ES, Quinn C, Walsh EM, Zolota V, Glynn SA, Callagy G. O'Loughlin M, et al. Among authors: andreu x. Breast Cancer Res Treat. 2018 Aug;171(1):1-9. doi: 10.1007/s10549-018-4825-8. Epub 2018 May 17. Breast Cancer Res Treat. 2018. PMID: 29774470
Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers.
Cserni G, Wells CA, Kaya H, Regitnig P, Sapino A, Floris G, Decker T, Foschini MP, van Diest PJ, Grabau D, Reiner A, DeGaetano J, Chmielik E, Cordoba A, Andreu X, Zolota V, Charafe-Jauffret E, Ryska A, Varga Z, Weingertner N, Bellocq JP, Liepniece-Karele I, Callagy G, Kulka J, Bürger H, Figueiredo P, Wesseling J, Amendoeira I, Faverly D, Quinn CM, Bianchi S. Cserni G, et al. Among authors: andreu x. Virchows Arch. 2016 Apr;468(4):473-81. doi: 10.1007/s00428-016-1909-x. Epub 2016 Jan 27. Virchows Arch. 2016. PMID: 26818833
32 results